
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Peter O’Donnell’s recent Applied Clinical Trials blog, ‘Who’s in charge of Medicines in Brussels?‘, has been overtaken by history, with the departure of Guido Rasi from his post of Executive Director of the European Medicines Agency.
Peter O’Donnell’s recent Applied Clinical Trials blog, ‘
At a time of flux in the European context for pharmaceuticals, Rasi’s moderate manner and capacity for strategic thinking were one reassurance amid so much uncertainty, writes Peter, and his removal is to be lamented.






